Eledoisin - CAS 69-25-0
Catalog number: 69-25-0
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C54H85N13O15S
Molecular Weight:
1188.41
COA:
Inquire
Targets:
Others
Description:
Eledoisin is an undecapeptide of mollusk origin and it belongs to the tachykinin family of neuropeptides. It was first isolated from the posterior salivary glands of two mollusk species Eledone muschata and Eledone aldovandi. Eledoisin has the amino acid sequence pGlu-Pro-Ser-Lys-Asp-Ala-Phe-Ile-Gly-Leu-Met-NH2. It is the Potent natural tachykinin receptor ligand.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Appearance:
White lyophilised solid
Synonyms:
eledonepeptide;ELEDOISIN;GLP-PRO-SER-LYS-ASP-ALA-PHE-ILE-GLY-LEU-MET-NH2;5-oxo-l-prolyl-l-prolyl-l-seryl-l-lysyl-l-aspartyl-l-alanyl-l-phenylalanyl-l-isoleucylglycyl-l-leucyl-l-methioninamide;PYR-PRO-SER-LYS-ASP-ALA-PHE-ILE-GLY-LEU-MET-NH2;PYR-PSKDAFIGLM;(3S)-3-[[(2S)-6-amino-2-[[(2S)-3-hydroxy-2-[[(2S)-1-[(2S)-5-oxopyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]hexanoyl]amino]-4-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
Solubility:
Soluble to 0.20 mg/ml in water
Storage:
-20℃ Freezer
MSDS:
Inquire
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Milligrams-Grams
Density:
1.289 g/cm3
InChIKey:
AYLPVIWBPZMVSH-FCKMLYJASA-N
InChI:
InChI=1S/C54H85N13O15S/c1-7-30(4)44(53(81)57-27-42(70)60-36(24-29(2)3)49(77)61-33(45(56)73)20-23-83-6)66-50(78)37(25-32-14-9-8-10-15-32)63-46(74)31(5)58-48(76)38(26-43(71)72)64-47(75)34(16-11-12-21-55)62-51(79)39(28-68)65-52(80)40-17-13-22-67(40)54(82)35-18-19-41(69)59-35/h8-10,14-15,29-31,33-40,44,68H,7,11-13,16-28,55H2,1-6H3,(H2,56,73)(H,57,81)(H,58,76)(H,59,69)(H,60,70)(H,61,77)(H,62,79)(H,63,74)(H,64,75)(H,65,80)(H,66,78)(H,71,72)/t30-,31-,33-,34-,35-,36-,37-,38-,39-,40-,44-/m0/s1
Canonical SMILES:
CCC(C)C(C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(CCSC)C(=O)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C2CCCN2C(=O)C3CCC(=O)N3
1.Structural heterogeneity of doubly-charged peptide b-ions.
Li X1, Huang Y, O'Connor PB, Lin C. J Am Soc Mass Spectrom. 2011 Feb;22(2):245-54. doi: 10.1007/s13361-010-0036-1. Epub 2011 Jan 29.
Performing collisionally activated dissociation (CAD) and electron capture dissociation (ECD) in tandem has shown great promise in providing comprehensive sequence information that was otherwise unobtainable by using either fragmentation method alone or in duet. However, the general applicability of this MS(3) approach in peptide sequencing may be undermined by the formation of non-direct sequence ions, as sometimes observed under CAD, particularly when multiple stages of CAD are involved. In this study, varied-sized doubly-charged b-ions from three tachykinin peptides were investigated by ECD. Sequence scrambling was observed in ECD of all b-ions from neurokinin A (HKTDSFVGLM-NH(2)), suggesting the presence of N- and C-termini linked macro-cyclic conformers. On the contrary, none of the b-ions from eledoisin (pEPSKDAFIGLM-NH(2)) produced non-direct sequence ions under ECD, as it does not contain a free N-terminal amino group. ECD of several b-ions from Substance P (RPKPQQFFGLM-NH(2)) showed series of c(m)-Lys fragment ions which suggested that the macro-cyclic structure may also be formed by connecting the C-terminal carbonyl group and the ε-amino group of the lysine side chain.
2.Characterization of receptors for two Xenopus gastrointestinal tachykinin peptides in their species of origin.
Johansson A1, Liu L, Holmgren S, Burcher E. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):35-45. Epub 2004 Jul 2.
Two tachykinin peptides, bufokinin and Xenopus neurokinin A (X-NKA) were recently isolated from Xenopus laevis. In this study we investigated the tachykinin receptors in the Xenopus gastrointestinal tract. In functional studies using stomach circular muscle strips, all peptides had similar potencies (EC50 values 1-7 nM). The rank order of potency to contract the intestine was physalaemin (EC50 1 nM)> or =bufokinin (EC50 3 nM)>substance P (SP)> or =cod SP>NKA>>X-NKA (EC50 1,900 nM). No maximum response could be obtained for [Sar9,Met(O2)11]SP, eledoisin and kassinin. In stomach strips, the mammalian tachykinin receptor antagonists RP 67580 (NK1) and MEN 10376 (NK2) had agonistic effects but did not antagonize bufokinin or X-NKA. In intestinal strips, RP 67580 (1 microM) reduced the maximal response to X-NKA but not bufokinin, while MEN 10376 was ineffective. [125I]BH-bufokinin bound with high affinity to a single class of sites, of KD 213+/-35 (stomach) and 172+/-9.
3.Eledoisin and Kassinin, but not Enterokassinin, stimulate ion transport in frog skin.
Lippe C1, Bellantuono V, Ardizzone C, Cassano G. Peptides. 2004 Nov;25(11):1971-5.
In frog skin, tachykinins stimulate the ion transport, estimated by measuring the short-circuit current (SCC) value, by interacting with NK1-like receptors. In this paper we show that Kassinin (NK2 preferring in mammals) increases the SCC, while Enterokassinin has no effect. Therefore, either 2 Pro residues or 1 Pro and 1 basic amino acid must be present in the part exceeding the C-terminal pentapeptide. Eledoisin (NK3 preferring in mammals) stimulation of SCC is reduced by CP99994 and SR48968 (NK1 and NK2 antagonists) and not affected by SB222200 (NK3 antagonist). None of the three antagonists affects Kassinin stimulation of SCC.
4.Iatrogenic dry eye disease: an eledoisin/carnitine and osmolyte drops study.
Nebbioso M1, Evangelista M, Librando A, Plateroti AM, Pescosolido N. Biomed Pharmacother. 2013 Sep;67(7):659-63. doi: 10.1016/j.biopha.2013.07.001. Epub 2013 Jul 12.
BACKGROUND: To evaluate the effects of an eye drop containing eledoisin and carnitine in patients suffering from primary open-angle glaucoma (POAG) and ocular discomfort syndrome secondary to a chronically treated with eye drops containing benzalkonium chloride (BAK) as preservative. The dry eye disease was defined as a multifactorial drop disease concerning tears and ocular surface, which brings to discomfort symptoms and visual disorders with potential damage to the ocular surface. Several studies underlined the beneficial effects of secretagogues drugs, such as eledoisin. It is a neuro-peptide extracted from the salivary glands of some shellfishes. Recently, it has been also showed the protective role of carnitine in respect of the ocular surface exposed to the tear film hyperosmolarity.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 792957-74-5 ER-000444793

ER-000444793
(CAS: 792957-74-5)

ER-000444793, a potent inhibitor of mitochondrial permeability transition pore (mPTP) opening, inhibits mPTP with an IC50 of 2.8 μM. R-000444793 neither affecte...

CP-432
(CAS: 431990-08-8)

CP-432 is an EP4 prostaglandin agonist , potential useful for the treatment of glaucoma and ocular hypertension.

LY 181984
(CAS: 3955-50-8)

LY 181984 is an antitumor sulfonylurea.

CAS 1019640-33-5 Sitamaquine tosylate

Sitamaquine tosylate
(CAS: 1019640-33-5)

Sitamaquine tosylate is a dose-dependent and orally bioactive inhibitor of complex II (succinate dehydrogenase or SDH) of the respiratory chain in digitonin-per...

CAS 41451-75-6 Bruceantin

Bruceantin
(CAS: 41451-75-6)

Bruceantin is first isolated from Brucea antidysenterica, a tree used in Ethiopia for the treatment of cancer, and activity was observed against B16 melanoma, c...

CAS 1462249-75-7 PFK-158

PFK-158
(CAS: 1462249-75-7)

PFK-158, also known as ACT-PFK-158, is an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases (PFK-2/FBPase) isoform 3 (PFKFB3) and derivative of...

FR 75513
(CAS: 127975-78-4)

FR 75513 is a 1,1'-biphenyl-2,6-dicarboxylic acid diester compound with inhibitory activity on guinea-pig detrusor muscle contraction at electrical field stimul...

CAS 162784-72-7 7-Epi-10-oxo-docetaxel

7-Epi-10-oxo-docetaxel
(CAS: 162784-72-7)

Docetaxel Impurity

Mirin
(CAS: 1198097-97-0)

Mirin is a Mre11-Rad50-Nbs1 (MRN)-ATM pathway inhibitor. .

CAS 486-16-8 Carbinoxamine

Carbinoxamine
(CAS: 486-16-8)

Carbinoxamine is a antihistamine and anticholinergic agent used in the treatment of severe itching in patients with CD5.

CAS 343306-79-6 Sugammadex

Sugammadex
(CAS: 343306-79-6)

Sugammadex, a modified γ-cyclodextrin, with a lipophilic core and a hydrophilic periphery, is an agent for reversal of neuromuscular blockade by the agent rocu...

LY 135305
(CAS: 123199-75-7)

LY 135305 is a bio-active molecular under the development of Eli Lilly. It can inhibit spontaneous lung metastasis in a dose-dependent manner.

CAS 721-50-6 Prilocaine

Prilocaine
(CAS: 721-50-6)

Prilocaine is a local anesthetic of the amino amide type.

CAS 119-41-5 Efloxate

Efloxate
(CAS: 119-41-5)

Efloxate, a flavone derivative, could be effective in the treatment of chronic coronary insufficiency and angina pectoris for acting as a vasodilator.

CAS 205934-46-9 (R)-(-)-PK 11195

(R)-(-)-PK 11195
(CAS: 205934-46-9)

(R)-(-)-PK 11195 is the (R)-enantiomer of PK 11195, which is a peripheral benzodiazepine antagonist with high affinity for PBR in all species. It is used as a d...

CAS 54-91-1 Pipobroman

Pipobroman
(CAS: 54-91-1)

Integrin Antagonist 1 hydrochloride
(CAS: 1629249-40-6)

Integrin Antagonist 1 hydrochloride, a naphthyridine derivative, is a small molecule antagonist of integrin αvβ6. In the Fluorescence Polarisation Assay: human ...

CAS 20362-31-6 Arctiin

Arctiin
(CAS: 20362-31-6)

Arctiin has shown to be a suppressor of cyclin D1 protein expression in multiple types of human tumor cells, such as osteosarcoma, lung, colorectal, cervical, b...

CAS 105816-04-4 Nateglinide

Nateglinide
(CAS: 105816-04-4)

Nateglinide(Starlix) is an insulin secretagog agent that lowers blood glucose levels by stimulating insulin secretion from the pancreas. It achieves this by clo...

FR-190809
(CAS: 215589-63-2)

FR-190809 is a potent and orally efficacious ACAT inhibitor potentially for the treatment of Lipoprotein Disorders.

Chemical Structure

CAS 69-25-0 Eledoisin

Quick Inquiry

Verification code

Featured Items